Home / Treatments / Sedatives Hypnotics
Sedatives Hypnotics denials: what the review data shows
Independent reviewers have decided 77 published cases where an insurer denied Sedatives Hypnotics — and they overturned the insurer 33.8% of the time. A denial for Sedatives Hypnotics is a starting position, not a final answer.
Published decisions
77
2001–2026
Overturned
33.8%
26 denials reversed
Conditions behind sedatives hypnotics denials
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Insomnia | 25 | 28% |
| Anxiety | 10 | 30% |
| Depression | 7 | 42.9% |
| Narcolepsy | 7 | 71.4% |
| Bipolar Disorder | 4 | 0% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 74 | 33.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 33.3% |
Typical time to a decision
17 days
Most land between 7 and 21 days
Handled as urgent
29.9%
Expedited when a delay would cause harm
Recent direction
Rising
25% → 72.7% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for brand name medication, Lunesta.Findings: According to a study, “Insomnia disorder is defined in the International Classification of Sleep Disorders, Third Edition, as a complaint of trouble initiating or maintaining sleep which is associated with daytime consequences and is not attributable to environmental circumstances or inadequate opportunity to sleep. The disorder is identified as chronic when it has persisted for at least three months at a frequency of at least three times per week.” The study further states, “Chronic insomnia is associated with numerous adverse effects on function, health, and quality of life.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for intravenous ketamine treatment (once every two weeks). At issue is whether the requested intravenous ketamine treatments (once every two weeks) to treat the enrollee’s mental health or substance use disorder are medically necessary as defined in Health and Safety code section 1374(a)(3)(A) set forth below. “Medically necessary treatment of a mental health or substance use disorder” means a service or product addressing the specific needs of that patient, for the purpose of preventing, diagnosing, or treating an illness, injury, condition, or its symptoms, including minimizing the progression of that illness, injury, condition, or its symptoms, in a manner that is all of the following: (i) in accordance with the generally accepted standards of mental health and substance use disorder care;…
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has a history of chronic pain, sickle cell disease and insomnia. The medical records indicate she takes multiple medications including Norco, an opiate pain medication. The provider noted the patient has had an increase in pain crisis in the last several years with the most recent on 1/30/22. There was no indication of any current complications. The patient was being treated for depression and the plan of care included a follow-up with the psychiatry department. There was no indication that the patient was having sleep disturbance. In an addendum, the patient was noted to need something for sleep. Venlafaxine was noted to be ineffective. In August the patient presented with acute abdominal and back pain.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Ambien 25mg.At issue in this case is whether the Ambien is medically necessary to treat the patient’s medical condition as defined in Health and Safety code section 1374(a)(3)(A) set forth below. “Medically necessary treatment of a mental health or substance use disorder” means a service or product addressing the specific needs of that patient, for the purpose of preventing, diagnosing, or treating an illness, injury, condition, or its symptoms, including minimizing the progression of that illness, injury, condition, or its symptoms, in a manner that is all of the following: (i) In accordance with the generally accepted standards of mental health and substance use disorder care. (ii) Clinically appropriate in terms of type, frequency, extent, site, and duration.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Sedatives Hypnoticswhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.